Poor survival with wild-type TP53 ovarian cancer?

Gynecologic Oncology

Volumn 130, Issue 3, 2013, Pages 565-569

  Wong, Kwong Kwok ^a,b   Izaguirre, Daisy I ^a,b   Kwan, Suet Yan ^a,b   King, Erin R ^a   Deavers, Michael T ^a   Sood, Anil K ^a   Mok, Samuel C ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Collagen; EDA2R; Ovarian cancer p53 mutation; Survival statistics; VI; Wild type p53

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P53;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; FROZEN SECTION; GENE EXPRESSION; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; MIXED MULLERIAN TUMOR; NONSENSE MUTATION; OVARY CARCINOMA; OVARY SEROUS CYSTADENOCARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SURVIVAL TIME; WILD TYPE;

COLLAGEN VI; EDA2R; OVARIAN CANCER; P53 MUTATION; SURVIVAL STATISTICS; WILD-TYPE P53;

CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; KAPLAN-MEIER ESTIMATE; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROTEIN ARRAY ANALYSIS; SEQUENCE ANALYSIS, RNA; UP-REGULATION; XEDAR RECEPTOR;

EID: 84882448110     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.06.016     Document Type: Article

References (31)

1. P. de Graeff, A.P. Crijns, S. de Jong, M. Boezen, W.J. Post, and E.G. de Vries Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis Br J Cancer 101 2009 149 159
2. E.V. Hogdall, L. Christensen, C.K. Hogdall, K. Frederiksen, S. Gayther, and J. Blaakaer Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas APMIS 116 2008 400 409
3. K.M. Darcy, W.E. Brady, J.W. McBroom, J.G. Bell, R.C. Young, and W.P. McGuire Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study Gynecol Oncol 111 2008 487 495
4. F. Bartel, J. Jung, A. Bohnke, E. Gradhand, K. Zeng, and C. Thomssen Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival Clin Cancer Res 14 2008 89 96
5. Consortium TCGA Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
6. A.A. Ahmed, D. Etemadmoghadam, J. Temple, A.G. Lynch, M. Riad, and R. Sharma Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary J Pathol 221 2010 49 56
7. T. Biosig http://tcga.lbl.gov:8080/biosig/tcgadownload.do
8. Portal TCGAD https://tcga-data.nci.nih.gov/tcga/
9. P. Van Loo, G. Nilsen, S.H. Nordgard, H.K. Vollan, A.L. Borresen-Dale, and V.N. Kristensen Analyzing cancer samples with SNP arrays Methods Mol Biol 802 2012 57 72
10. E.S. Neeley, S.M. Kornblau, K.R. Coombes, and K.A. Baggerly Variable slope normalization of reverse phase protein arrays Bioinformatics 25 2009 1384 1389
11. C. Li, and W.H. Wong Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection Proc Natl Acad Sci U S A 98 2001 31 36
12. V.G. Tusher, R. Tibshirani, and G. Chu Significance analysis of microarrays applied to the ionizing radiation response Proc Natl Acad Sci U S A 98 2001 5116 5121
13. M.W. Hentze, and A.E. Kulozik A perfect message: RNA surveillance and nonsense-mediated decay Cell 96 1999 307 310
14. C. Tanikawa, C. Ri, V. Kumar, Y. Nakamura, and K. Matsuda Crosstalk of EDA-A2/XEDAR in the p53 signaling pathway Mol Cancer Res 8 2010 855 863
15. M.L. Smith, and A.J. Fornace Jr. Genomic instability and the role of p53 mutations in cancer cells Curr Opin Oncol 7 1995 69 75
16. R. Salani, R.J. Kurman, R. Giuntoli II, G. Gardner, R. Bristow, and T.L. Wang Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance Int J Gynecol Cancer 18 2008 487 491
17. K.Q. Cai, H. Wu, A.J. Klein-Szanto, and X.X. Xu Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity Gynecol Oncol 114 2009 18 25
18. D.M. Gershenson, C.C. Sun, D. Bodurka, R.L. Coleman, K.H. Lu, and A.K. Sood Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant Gynecol Oncol 114 2009 48 52
19. R. Vang, M. Shih Ie, and R.J. Kurman Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems Adv Anat Pathol 16 2009 267 282
20. J.H. Mao, J. Perez-Losada, D. Wu, R. Delrosario, R. Tsunematsu, and K.I. Nakayama Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene Nature 432 2004 775 779
21. T. Yokobori, K. Mimori, M. Iwatsuki, H. Ishii, I. Onoyama, and T. Fukagawa p53-altered FBXW7 expression determines poor prognosis in gastric cancer cases Cancer Res 69 2009 3788 3794
22. D.A. Garcia-Dios, D. Lambrechts, L. Coenegrachts, I. Vandenput, A. Capoen, and P.M. Webb High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma Gynecol Oncol 128 2013 327 334
23. E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, and B.A. Aksoy The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov 2 2012 401 404
24. L.K. Mullany, Z. Liu, E.R. King, K.K. Wong, and J.S. Richards Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival Endocrinology 153 2012 1638 1648
25. J.G. Jackson, V. Pant, Q. Li, L.L. Chang, A. Quintas-Cardama, and D. Garza p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer Cancer Cell 21 2012 793 806
26. S.K. Sinha, S. Zachariah, H.I. Quinones, M. Shindo, and P.M. Chaudhary Role of TRAF3 and - 6 in the activation of the NF-kappa B and JNK pathways by X-linked ectodermal dysplasia receptor J Biol Chem 277 2002 44953 44961
27. G. Yang, X. Xiao, D.G. Rosen, X. Cheng, X. Wu, and B. Chang The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer Clin Cancer Res 17 2011 2181 2194
28. C.A. Sherman-Baust, A.T. Weeraratna, L.B. Rangel, E.S. Pizer, K.R. Cho, and D.R. Schwartz Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells Cancer Cell 3 2003 377 386
29. A. Yemelyanova, R. Vang, M. Kshirsagar, D. Lu, M.A. Marks, and M. Shih Ie Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis Mod Pathol 24 2011 1248 1253
30. B.D. Lehmann, and J.A. Pietenpol Targeting mutant p53 in human tumors J Clin Oncol 30 2012 3648 3650
31. S. Kapoor The emerging anti-proliferative role of Nutlin-3 in the pathogenesis of systemic malignancies Cancer Biol Ther 14 2013 5